H Lundbeck A/S (HLUN-B) - Total Liabilities

Latest as of December 2025: Dkr29.11 Billion DKK ≈ $4.55 Billion USD

Based on the latest financial reports, H Lundbeck A/S (HLUN-B) has total liabilities worth Dkr29.11 Billion DKK (≈ $4.55 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

H Lundbeck A/S - Total Liabilities Trend (2004–2025)

This chart illustrates how H Lundbeck A/S's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

H Lundbeck A/S Competitors by Total Liabilities

The table below lists competitors of H Lundbeck A/S ranked by their total liabilities.

Company Country Total Liabilities
PrairieSky Royalty Ltd
TO:PSK
Canada CA$604.50 Million
Floor & Decor Holdings Inc
NYSE:FND
USA $3.16 Billion
Arcosa Inc
NYSE:ACA
USA $2.25 Billion
Hong Leong Financial Group Bhd
KLSE:1082
Malaysia RM309.77 Billion
Credit Acceptance Corporation
NASDAQ:CACC
USA $7.11 Billion
Landstar System Inc
NASDAQ:LSTR
USA $840.27 Million
Maha Properti Indonesia Tbk PT
JK:MPRO
Indonesia Rp485.51 Billion

Liability Composition Analysis (2004–2025)

This chart breaks down H Lundbeck A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.44 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.17 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.54 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how H Lundbeck A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for H Lundbeck A/S (2004–2025)

The table below shows the annual total liabilities of H Lundbeck A/S from 2004 to 2025.

Year Total Liabilities Change
2025-12-31 Dkr29.11 Billion
≈ $4.55 Billion
-8.94%
2024-12-31 Dkr31.97 Billion
≈ $5.00 Billion
+108.08%
2023-12-31 Dkr15.36 Billion
≈ $2.40 Billion
-7.86%
2022-12-31 Dkr16.67 Billion
≈ $2.61 Billion
+1.83%
2021-12-31 Dkr16.37 Billion
≈ $2.56 Billion
-14.07%
2020-12-31 Dkr19.06 Billion
≈ $2.98 Billion
-10.13%
2019-12-31 Dkr21.20 Billion
≈ $3.32 Billion
+142.04%
2018-12-31 Dkr8.76 Billion
≈ $1.37 Billion
+15.64%
2017-12-31 Dkr7.58 Billion
≈ $1.19 Billion
-27.97%
2016-12-31 Dkr10.52 Billion
≈ $1.65 Billion
-16.14%
2015-12-31 Dkr12.54 Billion
≈ $1.96 Billion
+3.54%
2014-12-31 Dkr12.11 Billion
≈ $1.89 Billion
+19.11%
2013-12-31 Dkr10.17 Billion
≈ $1.59 Billion
+21.55%
2012-12-31 Dkr8.37 Billion
≈ $1.31 Billion
+7.82%
2011-12-31 Dkr7.76 Billion
≈ $1.21 Billion
+12.71%
2010-12-31 Dkr6.88 Billion
≈ $1.08 Billion
-17.31%
2009-12-31 Dkr8.32 Billion
≈ $1.30 Billion
+65.99%
2008-12-31 Dkr5.01 Billion
≈ $784.60 Million
-2.46%
2007-12-31 Dkr5.14 Billion
≈ $804.36 Million
+5.65%
2006-12-31 Dkr4.87 Billion
≈ $761.35 Million
+17.64%
2005-12-31 Dkr4.14 Billion
≈ $647.17 Million
+12.71%
2004-12-31 Dkr3.67 Billion
≈ $574.18 Million
--

About H Lundbeck A/S

CO:HLUN-B Denmark Drug Manufacturers - Specialty & Generic
Market Cap
$5.50 Billion
Dkr35.14 Billion DKK
Market Cap Rank
#3356 Global
#21 in Denmark
Share Price
Dkr44.30
Change (1 day)
+2.50%
52-Week Range
Dkr29.64 - Dkr47.34
All Time High
Dkr90.49
About

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat maj… Read more